Julie M Vose speaks to Gemma Westcott, Commissioning Editor: Julie M Vose, is the Neumann M and Mildred E Harris Professor and Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center in Omaha (NE, USA). She received her medical degree, completed her residency in Internal Medicine, served as Chief Resident and completed a Fellowship in Hematology/Oncology at the University of Nebraska Medical Center. She also completed a sabbatical at Stanford University (CA, USA) and an MBA in Health Administration through the University of Colorado Business School (CO, USA). She has focused her career on translational research for improvement in the therapy of non-Hodgkin’s lymphoma (NHL) and Hodgkin lymphoma by developing a focused translational research program, evaluating novel therapies such as radiolabeled monoclonal antibodies, idiotype vaccine therapies, pathway-directed agents and stem cell transplantation. She has been recognized for her NHL research on a national and international level through research awards and invited lectureships worldwide. In addition, her funding record and publications in NHL therapy and transplantation research have added substantially to the research and knowledge base for the therapy of lymphoma. She is currently the 2015–2016 President of the American Society of Clinical Oncology.
QCan you tell our readers about your career & what led you to where you are today?
I started doing research with James Armitage in lymphoma when I was in medical school and have continued to do research with him and the team over the years. I did my hematology and oncology fellowship in the University of Nebraska Medical Center, where I am currently now the Chief of the Division of Oncology and Hematology. I started getting involved in American Society of Clinical Oncology (ASCO) early in my career when I was a fellow. I volunteered for many committees and became the chair of the education committee about 20 years ago. Eventually, I went to the board of directors and now fortunately I have been elected as president. Therefore, I have been very involved in oncology both at the research level as well as the national level at ASCO, and it has been a very rewarding career.